目的探讨成人原发性腹膜后畸胎瘤的临床特点、治疗方法及预后。方法 回顾性分析我院2001年1月—2018年9月收治的50例成年腹膜后畸胎瘤病人的临床资料及治疗、随访结果,并分析影响肿瘤复发的相关因素。结果 50例病人中男10例,女40例;良...目的探讨成人原发性腹膜后畸胎瘤的临床特点、治疗方法及预后。方法 回顾性分析我院2001年1月—2018年9月收治的50例成年腹膜后畸胎瘤病人的临床资料及治疗、随访结果,并分析影响肿瘤复发的相关因素。结果 50例病人中男10例,女40例;良性病变49例,恶性病变1例。所有病人均行手术治疗,7例病人术后复发。对影响腹膜后畸胎瘤复发的单因素分析结果显示,病人年龄、肿瘤是否残留与术后复发有关(χ^2 =5.05, P <0.05, P =0.002);进一步行多因素Logistic回归分析显示,肿瘤是否残留与术后复发显著相关( OR =13.320,95% CI =0.003~0.414, P <0.05)。结论 成人腹膜后畸胎瘤良性多见,主要治疗方式为手术治疗,术前应根据肿瘤的位置及大小选择合适的手术入路,力求完整切除肿瘤,避免复发。无论肿瘤是否良恶性,术后均应定期复查,以尽早发现肿瘤复发或恶变情况,并及时治疗。展开更多
Objective:To study the epidemiological features of pancreatic cystadenoma and cystadenocarcinoma in China during the last 10 years and to analyze the diagnosis and treatment.Methods:Reports on pancreatic cystadenoma a...Objective:To study the epidemiological features of pancreatic cystadenoma and cystadenocarcinoma in China during the last 10 years and to analyze the diagnosis and treatment.Methods:Reports on pancreatic cystadenoma and cystadenocarcinoma published from 2000 to 2009 were retrieved from various databases,such as WANFANG data,VIP web and China National Knowledge Infrastructure(CNKI).The epidemiological features of pancreatic cystadenoma and cystadenocarcinoma and its diagnosis and treatment were analyzed.Results:Totally 1 865 patients with pancreatic cystadenoma and cystadenocarcinoma were reported in China during the last 10 years.The male to female ratio was approximately 1:2.1.The accurate ages were reported in 1 536 cases,the average age of them was 50.8 years,whose average age from 40 to 60 years old accounted 75.9% of the patients.65.3% of the cases were located in East China and Central China.Abdominal pain was the main clinical manifestation and was found in 54.9% of the patients.Pancreatoduodenectomy and resection of body and tail of the pancreas were the main procedure for the treatment of pancreatic cystadenoma and cystadenocarcinoma.Conclusion:Pancreatic cystadenoma and cystadenocarcinoma were mainly found in older women in East and Central China.Preoperative diagnosis is difficult.Pancreatoduodenectomy and resection of pancreatic body and tail were the main procedure for the treatment of pancreatic cystadenoma and cystadenocarcinoma.展开更多
文摘目的探讨成人原发性腹膜后畸胎瘤的临床特点、治疗方法及预后。方法 回顾性分析我院2001年1月—2018年9月收治的50例成年腹膜后畸胎瘤病人的临床资料及治疗、随访结果,并分析影响肿瘤复发的相关因素。结果 50例病人中男10例,女40例;良性病变49例,恶性病变1例。所有病人均行手术治疗,7例病人术后复发。对影响腹膜后畸胎瘤复发的单因素分析结果显示,病人年龄、肿瘤是否残留与术后复发有关(χ^2 =5.05, P <0.05, P =0.002);进一步行多因素Logistic回归分析显示,肿瘤是否残留与术后复发显著相关( OR =13.320,95% CI =0.003~0.414, P <0.05)。结论 成人腹膜后畸胎瘤良性多见,主要治疗方式为手术治疗,术前应根据肿瘤的位置及大小选择合适的手术入路,力求完整切除肿瘤,避免复发。无论肿瘤是否良恶性,术后均应定期复查,以尽早发现肿瘤复发或恶变情况,并及时治疗。
文摘Objective:To study the epidemiological features of pancreatic cystadenoma and cystadenocarcinoma in China during the last 10 years and to analyze the diagnosis and treatment.Methods:Reports on pancreatic cystadenoma and cystadenocarcinoma published from 2000 to 2009 were retrieved from various databases,such as WANFANG data,VIP web and China National Knowledge Infrastructure(CNKI).The epidemiological features of pancreatic cystadenoma and cystadenocarcinoma and its diagnosis and treatment were analyzed.Results:Totally 1 865 patients with pancreatic cystadenoma and cystadenocarcinoma were reported in China during the last 10 years.The male to female ratio was approximately 1:2.1.The accurate ages were reported in 1 536 cases,the average age of them was 50.8 years,whose average age from 40 to 60 years old accounted 75.9% of the patients.65.3% of the cases were located in East China and Central China.Abdominal pain was the main clinical manifestation and was found in 54.9% of the patients.Pancreatoduodenectomy and resection of body and tail of the pancreas were the main procedure for the treatment of pancreatic cystadenoma and cystadenocarcinoma.Conclusion:Pancreatic cystadenoma and cystadenocarcinoma were mainly found in older women in East and Central China.Preoperative diagnosis is difficult.Pancreatoduodenectomy and resection of pancreatic body and tail were the main procedure for the treatment of pancreatic cystadenoma and cystadenocarcinoma.